FDA Issues Human Factors Guidance for Device Makers
Published Date: 5/29/2026
Notice
Summary
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
New Human Factors Submission Framework
On May 29, 2026, FDA issued final guidance that gives a risk-based framework describing the human factors information medical device manufacturers should include in marketing submissions to the Center for Devices and Radiological Health (CDRH). The guidance is intended to help make the FDA review process more efficient by clarifying what human factors content belongs in a submission.
60-Day Operationalization and Grace Period
FDA says the Agency and industry may need a minimum of 60 days to operationalize the policies in the guidance. For regulatory submissions currently pending after publication and for submissions received before August 1, 2026, FDA generally does not expect manufacturers will be ready to include the newly recommended information, though FDA will review any such information if it is submitted.
No New Paperwork Burden Declared
The guidance states it contains no new collection of information under the Paperwork Reduction Act. It refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0332, and others.
Guidance Is Nonbinding; Alternatives Allowed
FDA states the guidance represents its current thinking and is not binding on FDA or the public. Manufacturers may use an alternative approach if that approach satisfies the applicable statutes and regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10732 — Information Collection Requirement; Defense Federal Acquisition Regulation Supplement (DFARS), Contract Financing
The Department of Defense is asking to keep collecting info from businesses about contract payments for three more years. This affects about 1,000 companies who respond around 14,000 times a year, spending about 1.2 hours each time. They want your thoughts by July 28, 2026, to make sure the process stays useful and not too time-consuming.
Next: 2026-10735 — Obayashi-Jay Dee Joint Venture; Application for Permanent Variance and Interim Order; Grant of Interim Order; Request for Comments
The Obayashi-Jay Dee Joint Venture asked OSHA for special permission to change some safety rules while working in compressed-air environments on a tunnel project in New Hampshire. OSHA gave them a temporary green light starting May 29, 2026, while they decide if this change can be permanent. Workers and the public can share their thoughts by June 29, 2026, so everyone stays safe and the project keeps moving.